COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) (STRIDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00790517
Recruitment Status : Completed
First Posted : November 13, 2008
Last Update Posted : March 17, 2015
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
LifeWorks Northwest
Cascadia Behavioral Healthcare
Information provided by (Responsible Party):
Kaiser Permanente

Brief Summary:

The purpose of this study is to examine the effectiveness of a lifestyle intervention designed to reduce weight and diabetes risk in a population of individuals with mental illness who are also taking antipsychotic medications. We will examine the effectiveness of the intervention in

  1. reducing weight and Body Mass Index;
  2. reducing fasting insulin levels and increasing insulin sensitivity; and
  3. reducing total cholesterol and LDL cholesterol.

Condition or disease Intervention/treatment Phase
Weight Loss Diabetes Mellitus, Type 2 Psychotic Disorders Behavioral: Premier Lifestyle Intervention with DASH Diet Phase 2

Detailed Description:

Overweight and obesity are among the leading causes of preventable deaths in the US, primarily through their effects on Type II diabetes mellitus and other cardiovascular disease risk factors. Individuals with serious mental illness represent a large underserved population at greatly increased risk of obesity, diabetes, metabolic syndrome, and subsequent early mortality. These risks are amplified by the antipsychotic agents that are often prescribed to treat these mental conditions.

Although strong evidence indicates that lifestyle interventions are effective at reducing weight and other diabetes risk factors in general populations, and pilot and feasibility studies suggest that such interventions will be effective with individuals who have mental illnesses, no large-scale translational trials have examined such interventions in this population.

STRIDE is a randomized controlled trial to examine the effectiveness, in a mentally ill population, of a lifestyle intervention previously shown to be effective for reducing weight and diabetes risk factors. We target a group of individuals taking antipsychotic agents (n = 280) who receive treatment in one of two clinical settings-a publicly funded behavioral health care clinic and a non-profit private health plan. Counselors from each clinical setting will be trained in the intervention and paired with study staff to deliver it, increasing generalizability, and improving the probability of future adoption. The intervention promotes moderate calorie reduction, dietary changes, and increased energy expenditure, and is based on current clinical practice guidelines for treating obesity and cardiovascular disease.

Specific aims test the hypotheses that the intervention is more effective than usual care in: 1) reducing weight and Body Mass Index; 2) reducing fasting insulin levels and increasing insulin sensitivity; and 3) reducing total cholesterol and LDL cholesterol. A fourth aim explores effects of motivation, social support, and outcomes expectancies on primary outcomes, and moderators of intervention effectiveness (ethnicity, gender, mental illness diagnostic group, medication type, metabolic syndrome) on outcomes.

Implementation and process evaluations will assess the fidelity of intervention delivery, evaluate its acceptability; identify components participants find most and least helpful; identify barriers to, and facilitators of, lifestyle changes; and evaluate the effects of the intervention on body image, psychiatric symptoms, adherence to antipsychotic medications, quality of life, health-related self-efficacy, health, functional status, and social support. Cost-effectiveness analyses will evaluate incremental costs of producing change in each primary outcome (weight, BMI, fasting insulin levels, insulin sensitivity, and cholesterol).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Reducing Weight and Diabetes Risk in an Underserved Population
Study Start Date : June 2009
Actual Primary Completion Date : September 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Experimental: 1
Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
Behavioral: Premier Lifestyle Intervention with DASH Diet
Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
Other Name: DASH Diet

No Intervention: 2
Usual care

Primary Outcome Measures :
  1. Body Mass Index [ Time Frame: 6, 12, 24 months ]
  2. Weight [ Time Frame: 6, 12, 24 months ]
  3. Insulin sensitivity [ Time Frame: 6, 12, 24 months ]
  4. Fasting insulin levels [ Time Frame: 6, 12, 24 months ]
  5. Cholesterol levels [ Time Frame: 6, 12, 24 months ]

Secondary Outcome Measures :
  1. Body Image [ Time Frame: 6, 12, 24 months ]
  2. Antipsychotic Medication Adherence [ Time Frame: 6, 12, 24 months ]
  3. Psychiatric Symptoms [ Time Frame: 6, 12, 24 months ]
  4. Health-related self-efficacy [ Time Frame: 6, 12, 24 months ]
  5. Social support for diet/weight loss [ Time Frame: 6, 12, 24 months ]
  6. Quality of life [ Time Frame: 6, 12, 24 months ]
  7. Health/functional status [ Time Frame: 6, 12, 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. age 18 and over
  2. stable on antipsychotic agents >1 month
  3. BMI in the range of 25-44.9 kg/m2
  4. approved by primary care provider or psychiatrist for participation (based on mental and physical health status)
  5. able and willing to provide informed consent
  6. access to telephone or e-mail (for maintenance phase)

Exclusion Criteria:

  1. children under age 18
  2. diagnosis of dementia
  3. psychiatrist or primary care provider indication of any medical or psychiatric contraindications for participating in a weight reduction/exercise program
  4. cardiovascular event within the past 6 months (if more remote history, eligible with primary care provider or psychiatrist approval)
  5. history of bariatric surgery
  6. cancer diagnosis or cancer treatment in the prior 2 years (except for non-melanoma skin cancer)
  7. currently pregnant or breastfeeding, or plan a pregnancy prior to the end of study participation
  8. mental health hospitalization in the 30 days prior to enrollment
  9. planning on moving out of the area before the 24-month follow-up assessment
  10. currently enrolled in a weight-reduction program

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00790517

Layout table for location information
United States, Oregon
Cascadia Behavioral Healthcare
Portland, Oregon, United States, 97207
Center for Health Research, Kaiser Permanente Northwest
Portland, Oregon, United States, 97227-1110
LifeWorks Northwest
Portland, Oregon, United States, 97229
Sponsors and Collaborators
Kaiser Permanente
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
LifeWorks Northwest
Cascadia Behavioral Healthcare
Layout table for investigator information
Principal Investigator: Carla A Green, PhD, MPH Center for Health Research, Kaiser Permanente Northwest
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kaiser Permanente Identifier: NCT00790517    
Obsolete Identifiers: NCT00866372
Other Study ID Numbers: R18DK076775 ( U.S. NIH Grant/Contract )
R18DK076775 ( U.S. NIH Grant/Contract )
First Posted: November 13, 2008    Key Record Dates
Last Update Posted: March 17, 2015
Last Verified: March 2015
Keywords provided by Kaiser Permanente:
Weight loss
Diabetes prevention
Serious mental illness
Antipsychotic medications
Lifestyle intervention
Antipsychotic Agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Body Weight
Weight Loss
Mental Disorders
Psychotic Disorders
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Body Weight Changes
Schizophrenia Spectrum and Other Psychotic Disorders